Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Amidst the current initiatives to develop more targeted anti-cancer therapies, T cell therapy has emerged as a potent and viable therapeutic intervention to eradicate tumour cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.
With 2 approved therapies and over 365 clinical / preclinical product candidates, the CAR-T cells therapies pipeline has evolved significantly over the last few years
More than 100 industry players are involved in developing T cell therapy; academic institutes continue to make significant contributions to the innovation in this field
The discovery of novel, disease-specific targets has opened up new avenues for the development of CAR-T based treatment options for a diverse range of cancer indications.
A number of prominent scientists have emerged as key opinion leaders in this domain, having led / presently leading various CAR-T therapy related clinical development efforts.
Over time, multiple generations of CAR constructs based on a variety of scFv fragments using different vector types, have been developed to improve therapeutic efficiency.
The adoption of marketed therapies indicates that this credible promise can be turned into reality by deploying diverse promotional strategies.
The growing optimism is also evident in the opinions expressed by several industry / academic stakeholders and on social media.
With a robust development pipeline and encouraging clinical outcomes, the CAR T cell therapy market is anticipated to grow at an annualized rate of over 50% and be worth USD 15 billion by 2030
You can also download the SAMPLE REPORT on CAR T cells therapy by Roots Analysis.
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.